Chem. J. Chinese Universities ›› 2020, Vol. 41 ›› Issue (12): 2648.doi: 10.7503/cjcu20200436

Previous Articles     Next Articles

Progress on Aptamer for Cancer Theranostics

DONG Qian1,2, LI Zhaoqian1,2, PENG Tianhuan1,2, CHEN Zhuo1,2(), TAN Weihong1,2,3()   

  1. 1.State Key Laboratory of Chemo/Bio-Sensing and Chemometrics,College of Chemistry and Chemical Engineering
    2.Hunan Key Laboratory of Molecular Science and Biomedicine Laboratory,College of Chemistry and Chemical Engineering,Hunan University,Changsha 410082,China
    3.Institute of Molecular Medicine(IMM),Renji Hospital,School of Medicine,College of Chemistry and Chemical Engineering,Shanghai Jiao Tong University,Shanghai 200127,China
  • Received:2020-07-08 Online:2020-12-10 Published:2020-12-09
  • Contact: CHEN Zhuo E-mail:zhuochen@hnu.edu.cn;tan@hnu.edu.cn
  • Supported by:
    ? Supported by the National Natural Science Foundation of China(21522501);the Natural Science Foundation of Hunan Province, China(2018JJ1007)

Abstract:

Aptamers are single-stranded oligonucleotides selected through a process known as Systematic Evolution of Ligands by Exponential enrichment(SELEX), showing a high selectivity towards their target molecules. The selectivity and affinity of aptamers are comparable to antibodies and even higher. They have the advantages of multiple targets, low immunogenicity, ease of accurate synthesis and modification, flexible and controllable design, which endow them as new molecular tools for early screening, diagnosis and targeting therapy. Therefore, aptamers have attracted extensive attention and have been applied in the field of cancer diagnosis and treatment. This review focused on the applications of aptamers in cancer diagnosis and treatment, and summarized systematically the research progresses made in recent years and discussed the prospective of the future development.

Key words: Aptamer, Targeting therapy, Molecular probe, Cancer diagnosis and treatment

CLC Number: 

TrendMD: